Protein related to Fragile X syndrome may be a new target for blood pressure medicines

Credit: Pixabay/CC0 Public domain

A new study in mice has identified FXR1, a protein from the same family implicated in fragile X syndrome, as a potential target for creating a new type of antihypertensive drug, according to preliminary research presented at the ‘American Heart Association. Vascular Discovery: From Genes to Medicine Scientific Sessions 2022. The meeting will be held May 12-14, 2022 in Seattle and is a global exchange of the latest advances in new and emerging scientific research in arteriosclerosis, thrombosis, vascular biology , peripheral vascular vessels. disease, vascular surgery and functional genomics.

Fragile X syndrome, or FXS, is the most common known cause of inherited intellectual disability caused by mutations on the X chromosome. The CDC estimates that FXS affects 1 in 7,000 men and 1 in 11,000 women born each year in the United States. FXS can cause developmental delays, learning disabilities, and behavioral problems, with symptoms being more severe in boys than in girls.

FXS is caused by mutations in the FMR1 gene, which codes for an RNA-binding protein FMRP that is thought to play a role in the development of connections between nerve cells in the brain.

FXR1 belongs to the same family of RNA-binding proteins as FMRP and is muscle-specific. RNA-binding proteins help turn genes on and off and are essential for many cellular processes.

“In my previous research on FXR1, I expected to see more transcription factors, translation factors, factors that regulate mRNA interaction with FXR1,” said Amanda St. Paul, lead author of study and holds a doctorate. candidate at the Lewis Katz School of Medicine at Temple University in Philadelphia. “It was really surprising to find that FXR1 binds to many actin-binding proteins and other proteins involved in the cytoskeleton.” Transcription and translation factors are proteins that help turn certain genes on and off. Actin proteins are responsible for muscle contraction and relaxation.

St. Paul and his colleagues developed a mouse model where FXR1 can be deleted in smooth muscle cells, the same type that make up blood vessels in humans. The mice were genetically modified so that the FXR1 gene could be deleted by administering the drug tamoxifen.

With the deletion of the FXR1 gene, the researchers noted that vascular smooth muscle cells behaved differently than those in mice with active FXR1.

“We found that vascular smooth muscle cells without FXR1 do not proliferate, they do not adhere, they do not migrate, activities that depend on a properly functioning cytoskeleton. And that’s all a vascular smooth muscle cell should do. “, said Saint-Paul.

The removal of FXR1 had another eye-opening consequence: “When you remove FXR1 from the smooth muscle of these mice, they also have reduced diastolic blood pressure compared to control mice,” St. Paul said.

The analysis revealed that:

  • Depletion of FXR1 decreased the ability of blood vessel cells to contract; and
  • When FXR1 is deleted, mice had reduced diastolic blood pressure compared to control mice. This was measured using telemetry, an in vivo measure of blood pressure.

According to St. Paul, these results suggest that targeting FXR1 in vascular smooth muscle cells, or the contractile pathway it regulates, may be a promising avenue for antihypertensive drug development. “A lot of drug targets don’t focus on the cytoskeleton. Since FXR1 is muscle-specific, it gives us a specific target and pathway to investigate further,” she said. “Millions of people suffer from high blood pressure; it’s important to find new ways to improve blood pressure.”

Future work by St. Paul and colleagues will investigate whether FXR1 activity in smooth muscle cells depends on its ability to interact with cytoskeletal proteins and whether deletion of FXR1 is effective in lowering blood pressure in a hypertensive mouse model.

A potential therapeutic target and biomarker of ovarian cancer

More information:
American Heart Association Vascular Discovery: From Genes to Medicine 2022 Scientific Sessions

Provided by the American Heart Association

Quote: Proteins linked to fragile X syndrome could be a new target for hypertension drugs (May 12, 2022) retrieved on May 12, 2022 from fragile-syndrome-blood-pressure .html

This document is subject to copyright. Except for fair use for purposes of private study or research, no part may be reproduced without written permission. The content is provided for information only.

Leave a Comment